Gene therapy shows promise in tackling X-linked RP
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Search
Search results
SB-007, we’ve been expecting you
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Meet our Trustee: Dr Samuel Godfrey
Sam joins Retina UK, bringing a blend of scientific expertise, strategic leadership, and communication experience gained from over a decade working at Cancer Research UK.
VG801 gene therapy shows early promise for Stargardt disease in phase 1/2 clinical trial
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.
Opus Genetics completes enrolment in phase 3 trial of OPGx-LCA5
Opus Genetics has completed enrolment in its registrational phase 3 clinical trial of OPGx-LCA5, an investigational gene therapy for LCA5-related Leber Congenital Amaurosis (LCA).
Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
e-Newsletter July 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Look Forward – Summer 2025 – Issue 186
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.